V
42.61
1.35 (3.27%)
| Previous Close | 41.26 |
| Open | 41.18 |
| Volume | 1,900,361 |
| Avg. Volume (3M) | 1,572,677 |
| Market Cap | 2,723,974,912 |
| Price / Book | 9.11 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 3.5 |
| Insider Activity | 0.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (Evercore ISI Group, 127.65%) | Buy |
| Median | 81.50 (91.27%) | |
| Low | 33.00 (Wedbush, -22.55%) | Hold |
| Average | 72.83 (70.92%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 40.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 19 Dec 2025 | 96.00 (125.30%) | Buy | 48.30 |
| 07 Nov 2025 | 52.00 (22.04%) | Buy | 24.19 | |
| Wedbush | 11 Dec 2025 | 33.00 (-22.55%) | Hold | 46.02 |
| Evercore ISI Group | 08 Dec 2025 | 97.00 (127.65%) | Buy | 45.03 |
| TD Cowen | 05 Dec 2025 | 73.00 (71.32%) | Buy | 44.90 |
| HC Wainwright & Co. | 10 Nov 2025 | 90.00 (111.22%) | Buy | 27.75 |
| B of A Securities | 16 Oct 2025 | 48.00 (12.65%) | Buy | 30.51 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ENRIGHT PATRICK G | 46.02 | - | 5,882 | 270,690 |
| TURNER WILLIAM D. | - | 45.03 | -10,000 | -450,300 |
| Aggregate Net Quantity | -4,118 | |||
| Aggregate Net Value ($) | -179,610 | |||
| Aggregate Avg. Buy ($) | 46.02 | |||
| Aggregate Avg. Sell ($) | 45.03 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ENRIGHT PATRICK G | Director | 11 Dec 2025 | Buy (+) | 5,882 | 46.02 | 270,690 |
| TURNER WILLIAM D. | Officer | 08 Dec 2025 | Automatic sell (-) | 10,000 | 45.03 | 450,300 |
| TURNER WILLIAM D. | Officer | 08 Dec 2025 | Option execute | 10,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |